<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on November 19, 2026 at 11:40 am by All in One SEO v5.0.5.1 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://helixgatebiotechreview.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>Helixgate</title>
		<link><![CDATA[https://helixgatebiotechreview.com]]></link>
		<description><![CDATA[Helixgate]]></description>
		<lastBuildDate><![CDATA[Thu, 19 Nov 2026 10:36:24 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://helixgatebiotechreview.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://phys.org/news/2026-11-cellular-recycling-gene-yields-hard.html]]></guid>
			<link><![CDATA[https://phys.org/news/2026-11-cellular-recycling-gene-yields-hard.html]]></link>
			<title>Switching off cellular recycling gene increases yields of hard-to-make drug target proteins</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 10:36:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/partner/cns-drug-discovery-ai-eeg/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/partner/cns-drug-discovery-ai-eeg/]]></link>
			<title>CNS drug discovery: How AI-powered EEG profiling can sharpen go/no-go decisions</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:34:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.labiotech.eu/in-depth/chinese-biotech-competition-european-biotech/]]></guid>
			<link><![CDATA[https://www.labiotech.eu/in-depth/chinese-biotech-competition-european-biotech/]]></link>
			<title>Chinese biotech competition and the payer squeeze are reshaping European biotech</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:34:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-livsayis-cemdisiran-generalized-myasthenia-gravis-6943.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-livsayis-cemdisiran-generalized-myasthenia-gravis-6943.html]]></link>
			<title>FDA Approves Livsayis (cemdisiran) for the Treatment of Generalized Myasthenia Gravis</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:03:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-lembaz-adrabetadex-improve-survival-infantile-onset-niemann-pick-type-c-6941.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-lembaz-adrabetadex-improve-survival-infantile-onset-niemann-pick-type-c-6941.html]]></link>
			<title>FDA Approves Lembaz (adrabetadex) to Improve Survival in Infantile-Onset Niemann-Pick Disease, Type C</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:03:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/newdrugs/fda-approves-infilbray-venglustat-neurological-manifestations-type-3-gaucher-6942.html]]></guid>
			<link><![CDATA[https://www.drugs.com/newdrugs/fda-approves-infilbray-venglustat-neurological-manifestations-type-3-gaucher-6942.html]]></link>
			<title>FDA Approves Infilbray (venglustat) to Treat Neurological Manifestations of Type 3 Gaucher Disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 09:03:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/novo-presents-preclinical-human-data-suggesting-role-amylin-calcitonin-receptor-activation-22690.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/novo-presents-preclinical-human-data-suggesting-role-amylin-calcitonin-receptor-activation-22690.html]]></link>
			<title>Novo Presents Preclinical and Human Data Suggesting a Role for Amylin and Calcitonin Receptor Activation in Preserving Bone During Weight Loss</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/cardiff-oncology-receives-fda-fast-track-designation-onvansertib-first-line-ras-mutated-metastatic-22692.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/cardiff-oncology-receives-fda-fast-track-designation-onvansertib-first-line-ras-mutated-metastatic-22692.html]]></link>
			<title>Cardiff Oncology Receives FDA Fast Track Designation for Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/uniquity-bio-announces-statistically-significant-clinically-meaningful-positive-topline-phase-2-22695.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/uniquity-bio-announces-statistically-significant-clinically-meaningful-positive-topline-phase-2-22695.html]]></link>
			<title>Uniquity Bio Announces Statistically Significant and Clinically Meaningful Positive Topline Phase 2 Results for Solrikitug in Eosinophilic Esophagitis</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/biogen-s-diranersen-demonstrates-increasing-clinical-benefit-two-years-early-alzheimer-s-22694.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/biogen-s-diranersen-demonstrates-increasing-clinical-benefit-two-years-early-alzheimer-s-22694.html]]></link>
			<title>Biogen’s Diranersen Demonstrates Increasing Clinical Benefit at Two Years in Early Alzheimer’s Disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/merck-announces-update-bellwave-clinical-development-program-evaluating-nemtabrutinib-22689.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/merck-announces-update-bellwave-clinical-development-program-evaluating-nemtabrutinib-22689.html]]></link>
			<title>Merck Announces Update on BELLWAVE Clinical Development Program Evaluating Nemtabrutinib</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/laboratoires-pierre-fabre-announce-fda-fast-track-designation-elticertinib-nsclc-22691.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/laboratoires-pierre-fabre-announce-fda-fast-track-designation-elticertinib-nsclc-22691.html]]></link>
			<title>Laboratoires Pierre Fabre Announce FDA Fast Track Designation for Elticertinib in NSCLC</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.drugs.com/clinical_trials/bristol-myers-squibb-presents-first-clinical-data-two-phase-3-studies-adept-program-evaluating-22693.html]]></guid>
			<link><![CDATA[https://www.drugs.com/clinical_trials/bristol-myers-squibb-presents-first-clinical-data-two-phase-3-studies-adept-program-evaluating-22693.html]]></link>
			<title>Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 07:51:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/pharmalot/2026/11/18/heidi-overton-fda-nomination-yanked-merck-cancer-drug-setback/?utm_campaign=rss]]></link>
			<title>STAT+: Pharmalittle: We’re reading about Overton FDA nomination being yanked, a Merck setback, and more</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 03:56:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/18/biotech-news-fda-discloses-reasons-for-rejecting-summit-drug/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/18/biotech-news-fda-discloses-reasons-for-rejecting-summit-drug/?utm_campaign=rss]]></link>
			<title>STAT+: FDA discloses reasons for rejecting Summit drug</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 03:56:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.statnews.com/2026/11/18/fda-after-heidi-overton-burning-questions-agency-future/?utm_campaign=rss]]></guid>
			<link><![CDATA[https://www.statnews.com/2026/11/18/fda-after-heidi-overton-burning-questions-agency-future/?utm_campaign=rss]]></link>
			<title>STAT+: 7 burning questions about the FDA’s post-Overton future</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 03:56:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.nature.com/articles/s41587-026-03405-9]]></guid>
			<link><![CDATA[https://www.nature.com/articles/s41587-026-03405-9]]></link>
			<title>Author Correction: The global patent landscape of bispecific antibodies: technological innovations and therapeutic applications</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 03:14:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/summits-rejection-letter-reveals-fdas-deeper-concerns-about-trial-design-safety]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/summits-rejection-letter-reveals-fdas-deeper-concerns-about-trial-design-safety]]></link>
			<title>Summit’s rejection letter reveals FDA’s deeper concerns about trial design, safety</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 02:33:32 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/fda/gsk-nabs-fda-greenlight-for-second-lung-cancer-asset-from-nuvalent-buy]]></guid>
			<link><![CDATA[https://www.biospace.com/fda/gsk-nabs-fda-greenlight-for-second-lung-cancer-asset-from-nuvalent-buy]]></link>
			<title>GSK nabs FDA greenlight for second lung cancer asset from Nuvalent buy</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 02:33:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biospace.com/business/government-actions-are-hitting-smaller-biotechs-the-hardest-report]]></guid>
			<link><![CDATA[https://www.biospace.com/business/government-actions-are-hitting-smaller-biotechs-the-hardest-report]]></link>
			<title>Government actions are hitting smaller biotechs the hardest: Report</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 02:33:28 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/gsk-gets-second-cancer-drug-approval-nuvalent-buy]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/gsk-gets-second-cancer-drug-approval-nuvalent-buy]]></link>
			<title>GSK gets second cancer drug approval from Nuvalent buy</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 01:21:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/white-house-drops-heidi-overton-pick-fda-chief]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/white-house-drops-heidi-overton-pick-fda-chief]]></link>
			<title>White House drops Heidi Overton pick for FDA chief</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 01:21:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/berens-niemann-pick-drug-lembaz-cleared-fda]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/berens-niemann-pick-drug-lembaz-cleared-fda]]></link>
			<title>Beren&#8217;s Niemann-Pick drug Lembaz cleared by FDA</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 01:21:24 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://pharmaphorum.com/news/msd-stops-trials-btk-inhibitor-blood-cancers]]></guid>
			<link><![CDATA[https://pharmaphorum.com/news/msd-stops-trials-btk-inhibitor-blood-cancers]]></link>
			<title>MSD stops trials of BTK inhibitor for blood cancers</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 01:21:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products]]></guid>
			<link><![CDATA[http://www.fda.gov/regulatory-information/search-fda-guidance-documents/use-bayesian-methodology-clinical-trials-drug-and-biological-products]]></link>
			<title>Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:43:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-regent-inc-issues-voluntary-nationwide-recall-three-lots-epinephrine-injection-usp-30-mg-30]]></guid>
			<link><![CDATA[http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/american-regent-inc-issues-voluntary-nationwide-recall-three-lots-epinephrine-injection-usp-30-mg-30]]></link>
			<title>American Regent, Inc. Issues Voluntary Nationwide Recall of Three Lots of Epinephrine Injection, USP 30 mg/ 30 mL (1 mg/mL) Due to the Presence of Particulate Matter and Lack of Assurance of Sterility</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:43:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide]]></guid>
			<link><![CDATA[http://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide]]></link>
			<title>FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:43:31 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/fda-information-session-generic-drug-research-needs-opportunities-fy-2027-12102026]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/fda-information-session-generic-drug-research-needs-opportunities-fy-2027-12102026]]></link>
			<title>FDA Information Session on Generic Drug Research Needs &amp; Opportunities for FY 2027 &#8211; 12/10/2026</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:43:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/science-and-research-drugs/drug-quality-sampling-and-testing-programs]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/science-and-research-drugs/drug-quality-sampling-and-testing-programs]]></link>
			<title>Drug Quality Sampling and Testing Programs</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:42:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/science-and-research-drugs/fdas-enhanced-approach-sampling-and-testing]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/science-and-research-drugs/fdas-enhanced-approach-sampling-and-testing]]></link>
			<title>FDA’s Enhanced Approach for Sampling and Testing</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:42:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/drug-alerts-and-statements/fda-introduces-new-approach-drug-quality-sampling-and-testing]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/drug-alerts-and-statements/fda-introduces-new-approach-drug-quality-sampling-and-testing]]></link>
			<title>FDA Introduces New Approach to Drug Quality Sampling and Testing</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:42:48 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/drug-supply-chain-integrity/internet-pharmacy-warning-letters]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/drug-supply-chain-integrity/internet-pharmacy-warning-letters]]></link>
			<title>Internet Pharmacy Warning Letters</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:41:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/report-state-pharmaceutical-quality]]></guid>
			<link><![CDATA[http://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/report-state-pharmaceutical-quality]]></link>
			<title>Report on the State of Pharmaceutical Quality</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:41:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/eco-nams-webinar-series-enhancing-regulatory-application-ecotoxicological-qsars-12032026]]></guid>
			<link><![CDATA[http://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/eco-nams-webinar-series-enhancing-regulatory-application-ecotoxicological-qsars-12032026]]></link>
			<title>Eco-NAMs Webinar Series | Enhancing Regulatory Application of Ecotoxicological QSARs &#8211; 12/03/2026</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:41:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease]]></guid>
			<link><![CDATA[http://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-neurological-symptoms-type-3-gaucher-disease]]></link>
			<title>FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease</title>
			<pubDate><![CDATA[Thu, 19 Nov 2026 00:41:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs]]></link>
			<title>What&#8217;s New Related to Drugs</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 21:47:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026]]></link>
			<title>Novel Drug Approvals for 2026</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 21:45:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals]]></guid>
			<link><![CDATA[http://www.fda.gov/about-fda/accelerating-rare-disease-cures-arc-program/rare-disease-drug-approvals]]></link>
			<title>Rare Disease Drug Approvals</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 21:44:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters]]></link>
			<title>Untitled Letters</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 20:59:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/narrative-review-highlights-real-world-patient-journey-in-tenosynovial-giant-cell-tumor/]]></guid>
			<link><![CDATA[https://bioengineer.org/narrative-review-highlights-real-world-patient-journey-in-tenosynovial-giant-cell-tumor/]]></link>
			<title>Narrative Review Highlights Real-World Patient Journey in Tenosynovial Giant Cell Tumor</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 20:22:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/stitchr-based-dual-aav-systems-enable-targeted-large-gene-delivery-in-neural-cells/]]></guid>
			<link><![CDATA[https://bioengineer.org/stitchr-based-dual-aav-systems-enable-targeted-large-gene-delivery-in-neural-cells/]]></link>
			<title>StitchR-Based Dual-AAV Systems Enable Targeted Large-Gene Delivery in Neural Cells</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 20:21:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://bioengineer.org/italian-experts-rate-igm-enriched-ivig-appropriate-for-specific-sepsis-phenotypes/]]></guid>
			<link><![CDATA[https://bioengineer.org/italian-experts-rate-igm-enriched-ivig-appropriate-for-specific-sepsis-phenotypes/]]></link>
			<title>Italian experts rate IgM-enriched IVIg appropriate for specific sepsis phenotypes</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 20:21:09 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-paid-facilities-list]]></guid>
			<link><![CDATA[http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-paid-facilities-list]]></link>
			<title>GDUFA Paid Facilities List</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 19:04:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661437/biopharmas-should-invest-in-tools-to-close-biological-ai-s-data-gaps-a-perspective?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661437/biopharmas-should-invest-in-tools-to-close-biological-ai-s-data-gaps-a-perspective?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Biopharmas should invest in tools to close biological AI’s data gaps — a Perspective</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 17:00:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661645/sellas-aml-win-strengthens-case-for-cancer-vaccines-in-recurrence-prevention?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661645/sellas-aml-win-strengthens-case-for-cancer-vaccines-in-recurrence-prevention?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Sellas’ AML win strengthens case for cancer vaccines in recurrence prevention</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 17:00:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661647/isomorphic-raises-record-5b-round-before-naming-a-development-candidate?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661647/isomorphic-raises-record-5b-round-before-naming-a-development-candidate?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Isomorphic raises record $5B round before naming a development candidate</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 17:00:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biocentury.com/article/661656/summit-setback-reinforces-fda-pushback-on-china-heavy-data?utm_source=bc_rss&amp;utm_medium=rss]]></guid>
			<link><![CDATA[https://www.biocentury.com/article/661656/summit-setback-reinforces-fda-pushback-on-china-heavy-data?utm_source=bc_rss&amp;utm_medium=rss]]></link>
			<title>Summit setback reinforces FDA pushback on China-heavy data</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 17:00:10 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></guid>
			<link><![CDATA[http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files]]></link>
			<title>Drugs@FDA Data Files</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 14:50:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://www.biopharmadive.com/news/marrow-therapeutics-sickle-cell-beta-thalassemia-drug/874789/]]></guid>
			<link><![CDATA[https://www.biopharmadive.com/news/marrow-therapeutics-sickle-cell-beta-thalassemia-drug/874789/]]></link>
			<title>Marrow sets out to challenge genetic medicines for severe blood diseases</title>
			<pubDate><![CDATA[Wed, 18 Nov 2026 14:48:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://helixgatebiotechreview.com/]]></guid>
			<link><![CDATA[https://helixgatebiotechreview.com/]]></link>
			<title>Home</title>
			<pubDate><![CDATA[Mon, 07 Sep 2026 03:39:54 +0000]]></pubDate>
		</item>
				</channel>
</rss>
